Author

Josiana Limones

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5090989224

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

2022 · Luciano J. Costa, Shaji K Kumar, et al. · Blood · 38

OA-10 BMS-986453, a Dual-Targeting BCMA × GPRC5D Autologous CAR T Cell Therapy in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results From a Phase 1 Trial

2026 · Doris Hansen, Sham Mailankody, et al. · Clinical Lymphoma Myeloma & Leukemia

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

2025 · Courtney DiNardo, Eduardo Rodríguez-Arbolí, et al. · Blood

Works count: 3

Citation count: 38

H-index: 1

I10-index: 1